Camelid TB Serology Quarterly Report: 1st April to 30th June 2017
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 9
Report Period 1st April to 30th June 2017
Issued 05 July 2017

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test comprises two separate antibody tests in a test package that can be applied
flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation
respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA
Project FT1477 as follows (see also Rhodes et al., 2012);
Sensitivity = 81.3% [71.9-91.6]    [95% confidence intervals]
Specificity = 95.8% [93.3-98.2]
Parallel Test (e.g. confirmed breakdown herd test – for increased sensitivity):
Serial Test (e.g. movement test – for increased specificity):
Sensitivity = 55.8% [42.3-69.3]
Specificity = 99.7% 99.1-100]
N.B. The above combined test used by APHA from 1st October 2014 comprised the IDEXX ELISA and the Chembio
STAT-PAK lateral flow tests. Replacement of the STAT-PAK with the DPP VetTB lateral flow test by Chembio led to the
exchange of the STAT-PAK in the APHA camelid combined test with the new DPP VetTB test. APHA validation data
showed the DPP VetTB to have similar test specificities when used in the above combined test with the IDEXX ELISA
(Parallel 92.9% [89.6-96.2]; Serial 99.6% [98.7-100]). Preliminary data also suggested that the sensitivity of the DPP
VetTB is equivalent to that of the STAT-PAK.
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.
From November 2015 the enferplex ELISA was incorporated into APHA’s options for statutory camelid test purposes (the
enferplex may not be used for private testing). The 2-spot enferplex may be use as one of the two tests required for the
Parallel Test, while the 4-spot enferplex may be used as a stand-alone test in place of the high specificity Serial Test: the
sensitivity and specificity values of the two test options above (for increased sensitivity or increased specificity) are not
altered by this flexible use of test options.

Quarterly Camelid Serology Report
05 Jul 2017
Table 1a
Country
No.
Samples
Tested
England
663
Wales
14
Total for Q2
677
Number of Samples tested and Submission Reason  2017 Q2 (April - June)
Table 1b
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
20
PAR-TB
178
PAR-TRC
43
Parallel
Sum:
241
Serial
SER-COL
30
SER-CONT
391
SER-EPI
1
Serial
Sum:
422
Commercial/Private Testing SER-DIAG
1
SER-MVT
1
SER-RHT
12
Commercial/Private Testing
Sum:
14
Total for Q2
Sum:
677

Quarterly Camelid Serology Report
05 Jul 2017
Table 2a
Country
No.
Samples
Tested
England
1573
Wales
75
Non GB
10
Total for Q2
1658
Number of Samples tested and Submission Reason 2017 up to end of Q2 (January - June)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
58
PAR-TB
181
PAR-TRC
96
Parallel
Sum:
335
Serial
SER-COL
105
SER-CONT
857
SER-EPI
311
Serial
Sum:
1273
Commercial/Private Testing
SER-DIAG
11
SER-MVT
2
SER-RHT
37
Commercial/Private Testing
Sum:
50
Total for 2017 up to end
of Q2
1658

Quarterly Camelid Serology Report
05 Jul 2017
Table 3a
Submissions Received and Test Positivity in 2017 Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
1
20
1
5.0%
PAR-TB
5
178
60
33.7%
PAR-TRC
9
41
1
2.4%
Parallel
15
239
62
25.9%
Serial
SER-COL
4
18
1
5.6%
SER-CONT
30
391
2
0.5%
SER-EPI
1
1
1
100.0%
Serial
35
410
4
1.0%
Commercial/Private Testing
SER-DIAG
1
1
0
0
SER-MVT
1
1
1
100.0%
SER-RHT
2
12
0
0
Commercial/Private Testing
4
14
1
7.1%
England Total
54
663
67
10.1%
Wales
Parallel
PAR-TRC
1
2
1
50.0%
Parallel
1
2
1
50.0%
Serial
SER-COL
1
12
0
0
Serial
1
12
0
0
Wales Total
2
14
1
7.1%
Totals for Q2
56
677
68
10.0 %
Test Positivity in 2017 Q2 (April - June)

Quarterly Camelid Serology Report
05 Jul 2017
Table 3b
Submissions Received and Test Positivity in 2017 up to the end of Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
3
58
3
5.2%
PAR-TB
6
179
61
34.1%
PAR-TRC
13
94
4
4.3%
Parallel
22
331
68
20.5%
Serial
SER-COL
11
74
1
1.4%
SER-CONT
64
817
3
0.4%
SER-EPI
3
311
26
8.4%
Serial
78
1,202
30
2.5%
Commercial/Private Testing
SER-DIAG
1
1
0
0
SER-MVT
2
2
1
50.0%
SER-RHT
3
37
0
0
Commercial/Private Testing
6
40
1
2.5%
England Total
106
1,573
99
6.3%
Wales
Parallel
PAR-TB
1
2
0
0
PAR-TRC
1
2
1
50.0%
Parallel
2
4
1
25.0%
Serial
SER-COL
2
31
0
0
SER-CONT
6
40
1
2.5%
Serial
8
71
1
1.4%
Wales Total
10
75
2
2.7%
Non GB
Commercial/Private Testing
SER-DIAG
1
10
0
0
Commercial/Private Testing
1
10
0
0
Non GB Total
1
10
0
0
Totals up to
end Q2
117
1,658
101
6.1 %
Test Positivity in 2017 up to end of Q2 (January - June)

Quarterly Camelid Serology Report
05 Jul 2017
Submissions Received in 2017 up to end of Q2
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Totals up to end Q2
TC0503
Camelid TB Enferplex - 2
Spot
7
98
105
TC0603
Camelid TB Enferplex - 4
Spot
554
425
979
TC0615
Camelid TB DPP VetTB
antibody test
471
251
722
TC0867
Camelid TB Antibody
ELISA
431
155
586
Table 4: Number of samples Tested by Test Code